BiotechTube

RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small Cell Lung Cancer, NSCLC

Conditions

Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC

Trial Timeline

Jan 18, 2024 → Dec 1, 2028

NCT ID
NCT06162221

About RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805

RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805 is a phase 1/2 stage product being developed by REVOLUTION Medicines for Non-Small Cell Lung Cancer, NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06162221. Target conditions include Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non-Small Cell Lung Cancer, NSCLC were approved

Approved (20) Terminated (2) Active (0)
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅Gefitinib + gemcitabine + carboplatinAstraZenecaApproved
✅PembrolizumabMerckApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06162221Phase 1/2Recruiting

Competing Products

20 competing products in Non-Small Cell Lung Cancer, NSCLC

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
pemetrexed + erlotinibEli LillyPhase 2
35
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
LY2875358 + ErlotinibEli LillyPhase 2
35
AdjuvantInsight Molecular DiagnosticsPre-clinical
8
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
Enzastaurin HCLEli LillyPhase 2
35
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
25
pemetrexed + gemcitabineEli LillyPhase 2
35
ALIMTA + CarboplatinEli LillyPhase 2
35
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
29
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
47